Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

661 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.
Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M. Witzens-Harig M, et al. Among authors: scholz c. Ann Hematol. 2012 Nov;91(11):1765-72. doi: 10.1007/s00277-012-1534-y. Epub 2012 Aug 29. Ann Hematol. 2012. PMID: 22926531 Review.
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M, Meyer A, Stroux A, Viardot A, La Rosée P, Maschmeyer G, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M, Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz CW; East German Study Group for Hematology and Oncology (OSHO). Pouyiourou M, et al. Among authors: scholz cw. Ann Hematol. 2020 Dec;99(12):2821-2829. doi: 10.1007/s00277-020-04171-7. Epub 2020 Jul 30. Ann Hematol. 2020. PMID: 32734548
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger K, De Filippi R, Lindén O, Viardot A, Hess G, Lerch K, Neumeister P, Stroux A, Peuker CA, Pezzutto A, Pinto A, Keller U, Scholz CW. Rieger K, et al. Ann Hematol. 2022 Apr;101(4):781-788. doi: 10.1007/s00277-022-04781-3. Epub 2022 Feb 12. Ann Hematol. 2022. PMID: 35150296 Free PMC article.
661 results